The German Chronic Kidney Disease (GCKD) study: design and methods

Kai-Uwe Eckardt1, Barbara Bärthlein2, Seema Baid-Agrawal3, Andreas Beck2, Martin Busch4, Frank Eitner5, Arif B. Ekici6, Jürgen Floege5, Olaf Gefeller7, Hermann Haller8, Karl F. Hilgers1, Jan T. Kielstein9, Vera Krane10, Anna Köttgen11, Florian Kronenberg12, Peter Oefner13, Hans-Ulrich Prokosch12, André Reis9, Matthias Schmid1, Elke Schaeffer3, Ulla T. Schultheiss11, Susanne A. Seuchter1, Thomas Sitter1, Claudia Sommerer14, Gerd Walz11, Christoph Wanner10, Gunter Wolf4, Martin Zeier14 and Stephanie Titze1

1Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany, 2Chair of Medical Informatics, University of Erlangen-Nürnberg, Erlangen, Germany, 3Department of Nephrology and Intensive Care Medicine, Charité, Campus Virchow Clinic, University Medicine, Berlin, Germany, 4Department of Internal Medicine III, University of Jena, Jena, Germany, 5Division of Nephrology and Clinical Immunology, RWTH University of Aachen, Aachen Germany, 6Institute of Human Genetics, University of Erlangen-Nürnberg, Erlangen, Germany, 7Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nürnberg, Erlangen, Germany, 8Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany, 9Department of Nephrology, Ludwig-Maximilians University, Munich, Germany, 10Division of Nephrology, Department of Internal Medicine I, University of Würzburg, Würzburg, Germany, 11Division of Nephrology, Department of Medicine, University Hospital Freiburg, Freiburg, Germany, 12Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria, 13Institute of Functional Genomics, University of Regensburg, Regensburg, Germany and 14Division of Nephrology, Department of Medicine, University of Heidelberg, Heidelberg, Germany

Correspondence and offprint requests to: Kai-Uwe Eckardt; E-mail: kai-uwe.eckardt@uk-erlangen.de

Abstract

Background. Chronic kidney disease (CKD) is increasingly recognized as a global health problem. The conditions leading to CKD, the health impact of CKD and the prognosis differ markedly between affected individuals. In particular, renal failure and cardiovascular mortality are competing risks for CKD patients. Opportunities for targeted intervention are very limited so far and require an improved understanding of the natural course of CKD, of the risk factors associated with various clinical end points and co-morbidities as well as of the underlying pathogenic mechanisms.

Methods. The German Chronic Kidney Disease (GCKD) study is a prospective observational national cohort study. It aims to enrol a total of 5000 patients with CKD of various aetiologies, who are under nephrological care, and to follow them for up to 10 years. At the time of enrolment, male and female patients have an estimated glomerular filtration rate (eGFR) of 30–60 mL/min × 1.73m² or overt proteinuria in the presence of an eGFR > 60 mL/min × 1.73m². Standardized collection of biomaterials, including DNA, serum, plasma and urine will allow identification and validation of biomarkers associated with CKD, CKD progression and related complications using hypothesis-driven and hypothesis-free approaches. Patient recruitment and follow-up is organized through a network of academic nephrology centres collaborating with practising nephrologists throughout the country.

Conclusions. The GCKD study will establish one of the largest cohorts to date of CKD patients not requiring renal replacement therapy. Similarities in its design with other observational CKD studies, including cohorts that have already been established in the USA and Japan, will allow comparative and joint analyses to identify important ethnic and geographic differences and to enhance opportunities for identification of relevant risk factors and markers.

Keywords: biomarkers; cohort; epidemiology; prognosis; risk factors

Introduction

Uniform criteria for the definition and classification of chronic kidney disease (CKD) were first proposed in 2002 [1]. Since then, a growing body of evidence has established the importance of CKD with respect to both its prevalence and the associated adverse consequences. Most recently, a large meta-analysis initiated by the global organization ‘Kidney Disease: Improving Global Outcomes’ (KDIGO), which included data from
>1.5 million individuals, has demonstrated a progressive increase in all-cause mortality, cardiovascular mortality, acute kidney injury incidence and kidney disease progression with decreasing glomerular filtration rate (GFR) and increasing albuminuria [2]. These relationships were strikingly consistent across general population-based cohorts [3, 4], high-risk cohorts [5] and CKD cohorts [6]. CKD has also been identified as a strong and independent risk factor for specific cardiovascular events and complications [7].

Despite its public health impact, the underlying mechanisms and the full spectrum of pathophysiological and clinical consequences of CKD are poorly understood (Figure 1). The prognosis of CKD patients is highly variable and the individual risks are not predictable with sufficient precision. In particular, premature death and progression to end-stage renal disease (ESRD) are competing risks and it is unclear to which extent they are the culprits of similar or different disease pathways.

Emerging high-throughput technologies, including genomics, metabolomics and proteomics, offer vast opportunities for identification of novel risk factors and/or risk markers that reflect predisposition to CKD or are associated with the manifestation and progression of CKD and its consequences [8]. The application of these technologies requires biomaterials from well-phenotyped patient cohorts with a prospective evaluation of individual patient courses, in order to allow for an efficient search for discriminative molecular patterns that are associated with different outcomes. So far, the number of observational cohort studies specifically addressing CKD and its risk factors, and the number of patients enrolled in such cohorts worldwide is rather small. Less than 22,000 patients of >1.5 million individuals within the recent KDIGO meta-analysis were participants in CKD cohort studies and in only some of these cohorts, have biomaterials been collected [2]. The Chronic Renal Insufficiency Cohort (CRIC) has enrolled 3612 patients of diverse ethnicities in the USA [9]. The Chronic Kidney Disease Japan Cohort (CKD-JAC) has used a similar design to enrol 3000 Japanese patients [10]. Given the genetic and environmental heterogeneities, the results of these studies will not necessarily be generalizable to a central European population. In fact, international comparisons between the CKD prevalence and the progression to ESRD suggest important differences between populations [11].

We have therefore established the German Chronic Kidney Disease (GCKD) study, a national prospective observational cohort study, to characterize the burden and the course of CKD patients, to identify and validate novel risk factors and markers for the manifestation, progression and complications of CKD and to improve the understanding of the underlying pathophysiology.

Materials and methods

Study objectives

The main objective of the GCKD study is to establish a large cohort of ~5000 CKD patients with a moderate reduction in GFR and/or overt proteinuria at enrolment, who receive comparable medical care, and are followed prospectively for up to 10 years and in whom biomaterials are collected at baseline and at regular intervals during the course of the study.

The main specific aims of the study are (i) to identify and validate risk factors and markers associated with the progression of CKD and the development of ESRD, (ii) to identify and validate risk factors and markers associated with cardiovascular disease (CVD) events and CVD progression in the setting of CKD, (iii) to assess the interrelationship between risk factors for CKD and CVD progression, (iv) to determine gender-related differences in the risks for CKD and CVD progression and (v) to assess the consequences of CKD for general health, non-CVD morbidity and health-related quality of life (QOL). Additional aims are to contribute to the identification of risk factors and markers for the development of CKD through comparison with general population-based cohorts.

Study organization

The GCKD organizational structure integrates the advantages of a centralized project management and decentralized recruitment centres. The project management centre at the University of Erlangen-Nuremberg hosts the central database, the data coordinating centre and the central biobank. Recruitment is organized through nine regional centres at collaborating academic institutions in Aachen, Berlin, Erlangen, Freiburg, Hannover, Heidelberg, Jena, München and Würzburg. Each centre is anticipated to recruit and follow an average of 550 patients in collaboration with the local practising nephrologists.

Cohort participants

The GCKD study is enrolling male and female Caucasian patients who have been previously referred to a nephrologist providing outpatient care in a nephrology practice setting or in outpatient clinics of the participating university hospitals. Inclusion criteria include an age range of 18–74 years and moderately reduced estimated glomerular filtration rate (eGFR) (30–60 mL/min × 1.73 m², corresponding to CKD Stage 3) or ‘overt’ proteinuria, defined as an albumin excretion of >300 mg/g creatinine or a protein excretion of >500 mg/g creatinine or corresponding values of 24-h urinary excretion, in the presence of an GFR >60 mL/min × 1.73 m² (Table 1). The eGFR defining eligibility is estimated from a locally measured serum creatinine value using different assays, which are not necessarily isotope dilution mass spectrometry (IDMS) traceable and the 4-variable MDRD formula [12]. Albumin or protein excretion rate defining eligibility is taken from patient records using locally determined values. Exclusion criteria are active malignancy, NYHA IV heart failure, renal or any other transplantation, non-Caucasian origin and legal attendance. In contrast to the CRIC Study in the
USA, enrolment is not stratified for age, cause of disease or presence of diabetes mellitus [13].

Enrolment and study design

The regional centres inform practising nephrologists in their region about the GCKD Study. If they agree to collaborate, they screen incident and prevalent patients under their care for eligibility. Eligible patients are then contacted by their nephrologists, receive detailed information about the study and are asked about their willingness to participate. Following informed consent, patients are invited to meet members of the GCKD study team in the nephrologist’s practice or the outpatient clinic where they are under routine care. Flexibility is allowed to either combine the GCKD study visit with a routine visit or to make a special appointment according to physician and patient preferences.

Baseline phenotyping of patients

Baseline assessment includes anthropometric measures, three measurements of resting blood pressure using a standardized device, heart rate and single-lead ECG. Information is collected on socio-demographic factors, medical and family history and the use of prescription drugs and over the counter medications. In addition, patient questionnaires are used to assess health-related QOL [14], life-style factors and symp-

Table 1. Inclusion and exclusion criteria in the GCKD study

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age: 18–74 years</td>
<td>Non-Caucasian race</td>
</tr>
<tr>
<td>eGFR: 30–60 mL/min/1.73m² or eGFR: &gt; 60 mL/min/1.73m² and ‘overt’ albuminuria/proteinuria as defined by any of the following:</td>
<td>Solid organ transplantation or bone marrow transplantation</td>
</tr>
<tr>
<td>Albuminuria &gt; 500 mg/g creatinine</td>
<td>Active malignancy within 24 months prior to screening</td>
</tr>
<tr>
<td>Albuminuria &gt; 500 mg/day</td>
<td>Heart failure NYHA IV</td>
</tr>
<tr>
<td>Proteinuria &gt; 500 mg/g creatinine</td>
<td>Patients under legal attendance or unwilling to provide consent</td>
</tr>
<tr>
<td>Proteinuria &gt; 500 mg/day</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Synopsis of data obtained in the GCKD study

<table>
<thead>
<tr>
<th>GCKD data</th>
<th>Instruments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td>Modified Gothenburg scale</td>
</tr>
<tr>
<td>Anthropometric data</td>
<td>Rose questionnaire</td>
</tr>
<tr>
<td>Renal and cardiovascular history, renal biopsy history</td>
<td>Edinburgh claudication questionnaire</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>KDQOL 36</td>
</tr>
<tr>
<td>Medication, life style</td>
<td></td>
</tr>
<tr>
<td>Family history</td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td></td>
</tr>
<tr>
<td>Angina pectoris/dyspnoea</td>
<td></td>
</tr>
<tr>
<td>Intermittent claudication</td>
<td></td>
</tr>
<tr>
<td>QOL</td>
<td></td>
</tr>
<tr>
<td>Core laboratory parameters</td>
<td>Creative, cystatin C, urea, sodium, calcium, phosphate, albumin, C-reactive protein, total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol, uric acid, haemoglobin, haemoglobin A1C, Albumin, creatinine</td>
</tr>
<tr>
<td>Serum</td>
<td></td>
</tr>
<tr>
<td>Urine</td>
<td></td>
</tr>
</tbody>
</table>

*Since all samples are shipped frozen, the haemoglobin concentration and the concentration of haemoglobin A1C are determined in thawed whole blood.

Follow-up visits

Follow-up visits are planned in 2-year intervals. One year after each follow-up visit, structured phone interviews are conducted with patients enrolled in the study to assess their disease course and new-onset complications and hospitalization episodes during the past 12 months. In addition, the patient’s nephrologist is contacted annually to assess key information on patient health and the latest serum creatinine value. Patients will be followed until death, the end of the study or withdrawal of consent. Follow-up with an adjusted protocol will continue after the initiation of renal replacement therapy.

Collection of biological material for biobanking

Blood samples are collected at baseline for DNA extraction. At each visit, plasma, serum and spot-urine samples are collected, processed and shipped frozen to a central laboratory for routine clinical chemistry (Table 2) and to the central biobank for future analyses. Workflows to track sample processing, sample transportation and sample storage are quality assured and supported by a dedicated biobank management system [18].

Study outcomes

The main study end points are (i) mortality, (ii) decline in renal function, including doubling of serum creatinine and need for regular renal replacement therapy and (iii) cardiovascular events, including cardiac death, non-fatal myocardial infarction, hospitalization due to angina or heart failure, cardiac surgery and stroke. Additional clinically relevant events recorded include development of malignancies and hospitalization due to infection. Written reports on all hospitalizations will be collected and adjudicated will be performed according to a standardized protocol.

Data protection

The GCKD study has implemented a data protection concept according to the data protection recommendations of the platform for technology and methods for networked medical research (TMF; www.tmf-ev.de), supported by the German Ministry of Education and Research (www.bmbf.de). The study protocol was approved by local institutional review boards at each participating academic institution and the data protection concept was reviewed by the data protection officer of the State of Hessen. A core component is that each patient is assigned a unique pseudonym. Personal identification data are stored in regional centres only and are strictly separated from medical and research data, which are stored centrally. Biosamples are identified only with their unique sample identifier and no patient identification is stored within the biobank management system. A 2D-barcode system is used for tracking, storage and retrieval of all biosamples.

Statistical considerations

The sample size of the GCKD cohort of 5000 patients was chosen as a realistically attainable cohort size based on feasibility considerations. This sample size ensures adequate statistical power to differentiate subgroups showing different behaviours with respect to the primary end point. For example, even when focussing only on the expected 2700 patients who will stay under observation for the entire study, we will be able to differentiate between two equally sized subgroups according to a standardized difference in yearly GFR decline of 0.11 mL/min/1.73m² with a power of 80%. The sample size allows for detection of a hazard ratio of 1.2 in time-to-event analyses with at least 80% power over a wide range of plausible scenarios with different occurrence rates in two equally sized subgroups (assuming a constant hazard ratio over time). In event-based analyses, e.g. comparing the proportion of patients requiring chronic renal replacement therapy or developing cardiovascular complications between two subgroups, a similar effect size, i.e. a relative risk of 1.2, can be detected with a power of 80% in all plausible settings.

Baseline characteristics will be described using standard descriptive methods such as summary statistics and frequency tables. Parametric and non-parametric statistical approaches (such as contingency table analysis, regression and analysis of variance) will be used to compare subgroups at baseline. Because the intention of the GCKD Study is to analyse...
all patients recruited for the study (including patients with incomplete data and/or early drop out), focus will be given to statistical methods addressing the problem of missing data [19].

Kaplan–Meier analysis and Cox regression [20, 21] will be the principal approaches to analyse end points such as mortality and cardiovascular end points. Changes in serum creatinine levels will be analysed using mixed-effects models and generalized estimation equations [22, 23]. The latter approaches are able to handle repeated measurements and the heterogeneity of individual creatinine levels. Subgroup analyses will be carried out for diabetic and non-diabetic patients, across sex- and age-strata, for patients with specific etiologies of CKD and for different cardiovascular comorbidities and outcomes.

Quality assurance

A quality management concept was developed and is constantly controlled by an internal and an external quality management board. Measures to ensure high quality standards include the development of data entry and data management systems, training, certification and recertification of all personnel involved in data collection and testing of data collection procedures. A special tool was developed to control specific data sets by selected experts from the internal quality management board during the complete survey. A web-based Patient Interview Audit (PIA)-Tool (Seuchter SA, Schmid M, Titz S et al., unpublished data) is used to monitor if patient interviews are carried out according to the instructions to ensure accuracy and avoid information bias. The tool also allows for the detection of data entry errors. Continuous data cleaning is used to analyse routinely for missing, extreme or inconsistent values. Biosamples are collected, processed and stored by certified personnel according to standardized protocols.

Enrolment to date

Current enrolment (25 July 2011) comprises a total number of 3291 patients in 158 outpatient sites. It is anticipated that the recruitment period will end in 2012.

Discussion

The GCKD study is planned as one of the largest prospective observational cohort studies to date of CKD patients not requiring renal replacement therapy at the time of recruitment. Recruitment in collaboration with practising nephrologists across the country reflects the organization of nephrology care in Germany: the majority of patients under the supervision of a nephrologist are not being treated in large centres, but in decentralized practices, which are usually run in conjunction with dialysis facilities. Recruitment of patients already referred to a nephrologist is likely to impact on patient characteristics. Thus, we anticipate that the GCKD cohort as compared to the general population and patient populations under non-nephrological care or with undiagnosed CKD will be enriched with individuals with more advanced and more progressive disease, a greater level of complications and symptoms, a higher degree of proteinuria, a higher proportion of specific renal diseases causing CKD and an increased awareness and compliance. Further bias is possibly introduced by the voluntary non-random collaboration of nephrologists. While the selection process will limit the ability to generalize findings to other patient populations, it will minimize the known influence of different levels of care on patient outcomes. In fact, there is considerable evidence indicating that long-term outcome of CKD patients varies depending on whether they do or do not receive medical care guided by nephrologists [24–26]. Mitigation of this variable should therefore facilitate detection of patient-related variables that impact outcomes.

Within this given setting of patient care, we aimed to minimize further selection bias by choosing broad and non-restrictive inclusion criteria. The entry criterion of a GFR of 30–60 mL/min/1.73m² corresponds to the current definition of CKD Stage 3 [27], which is known to be the most prevalent stage of CKD in the general population [28]. The study of a common and relatively early stage of CKD may identify risk factors relatively early during the course of the disease and ultimately enable disease prevention in a large at-risk population. In addition, patients with overt proteinuria are also being enrolled if their eGFR is >60 mL/min/1.73m², in order to investigate the emerging evidence for the high incidence of adverse outcomes in this subpopulation of CKD patients [3].

Despite the decentralized organization of the study, trained and certified study personnel travel to the physicians’ practices to enrol the patients. They conduct patient interviews and perform physical assessment in a standardized way to decrease the intra- and inter-observer variability. Moreover, a particular emphasis is put on standardized biomaterial collection and analysis. Thus, a set of standard clinical chemistry variables is analysed in all patients at each visit in a central laboratory. Fresh serum, plasma and urine samples are frozen on dry ice within 2 h after collection and shipped frozen to a central biobank for storage at −80°C. The established procedures have proved to work well, with not a single set of samples lost or thawed prior to arrival at the biobank thus far. The drawback of this standardized procedure is that study resources do not allow for in-person investigation intervals <2 years. However, yearly standardized telephone interviews with patients and doctors performed between two visits capture important information on patient course and possible end points.

A variety of possible risk factors and markers for CKD progression and the manifestation of CVD and mortality in patients with CKD have been identified in recent years [8], and the GCKD cohort will allow validation of many of those factors. In addition, we aim to apply hypothesis-generating approaches to search for molecular patterns that discriminate different courses of disease in serum and urine. We will not routinely collect 24-h urine, which is a limitation for some analysis, but would increase the pre-processing variability. In addition, applying discriminatory methodology to spot urine samples will focus the profile identification on patterns that are less sensitive to sample timing and thus possibly have a higher utility in routine care.

Despite the diversity of causes leading to CKD, recent data suggest that there is a common genetic predisposition for the development of CKD [29, 30] apart from the predisposition to develop specific kidney diseases, such as e.g. polycystic kidney disease [31], IgA nephropathy [32], membranous nephropathy [33], diabetic [34] or hypertensive [35] nephropathy. Genetic analysis will therefore be another important cornerstone of the GCKD Study, using candidate gene approaches, genome-wide association studies in the entire patient group and whole-genome sequencing in selected patients. While the GCKD cohort itself has the potential to contribute to identification of yet unknown genetic factors associated with the future
course and complications of established CKD, comparisons with general populations, non-CKD populations and other high-risk populations have the potential to identify and/or confirm genetic variants predisposing to CKD. This goal can only be achieved in the context of large international consortia, as recently demonstrated [36, 37].

Conceptually, the GCKD cohort is intended as an open network and scaffold for ancillary studies addressing specific characteristics of CKD patients in subgroups of the main cohort. Planned and ongoing studies include an in-depth characterization of the cardiac, micro- and macro-vascular structure and function, analysis of physical activity and analysis of circulating immune cell patterns.

The GCKD study will also greatly benefit from and foster (inter)national collaboration. Comparison of patient characteristics and biomarker profiles between different cohorts will identify not only differences but also similarities and thereby lead to hypotheses regarding their importance. Candidate biomarkers or profiles identified in one cohort can be validated in other cohorts. Moreover, meta-analyses across studies result in an increased statistical power, which is of particular importance to identify risk factors of low effect size, including specific gene variants. To capitalize on existing expertise and facilitate comparative and joint analysis, design, parameter sets and definitions of the GCKD study were chosen in collaboration with the investigators of the CRIC study [9, 13]. CRIC has previously provided guidance for establishment of the Japanese CKD cohort study [10] and we envisage sustained benefits from multinational collaborative approaches in this area. In addition, core data sets from other recently established prospective cohort studies with a nephrological focus in Germany, receiving funding from a source which also supports the GCKD study (KfH Foundation), have been synchronized to facilitate future cross-population comparisons. These studies include a diabetes cohort and CKD studies in an elderly population [38] and in children [39].

In conclusion, the GCKD study will assemble a large well-characterized clinical cohort of CKD patients to better define the disease characteristics, to validate established and to identify novel risk factors and markers. The study aims to advance the understanding of CKD aetiology, manifestation, progression and complications, to identify novel molecular targets and to provide a basis for improved prevention as well as—ultimately—personalized therapy of CKD.

Acknowledgements. The GCKD study is funded by grants from the German Ministry of Education and Research (BMBF) (http://www.gesundheitsforschung-bmbf.de/de/2101.php; grant number 01ER0804) and the KfH Foundation for Preventive Medicine (http://www.kfh-stiftung-praeventivmedizin.de/stiftung.html). It is conducted under the auspices of the German Society of Nephrology (DGN) (http://www.dgn.eu). The list of GCKD Study Group is listed in Appendix.

The authors gratefully acknowledge excellent advice and generous support provided by Dr Harv Feldman and other members of the CRIC Study Steering Committee (USA) in designing the GCKD study protocol, study documents and procedures. Drs Gerjan Navis (NL) and Marc Froissart (F) provided helpful advice for setting up the GCKD study biobank.

Conflict of interest statement. None declared.

Appendix: The GCKD Study Group

Regional Study Centres

Technical University of Aachen
Frank Eitner, MD
Katharina Kehl, MD MPH
Elfrriede Ahrweiler, MPH
Sabine Ernst
Mario Unger, RN
Jürgen Floege, MD
Charité, Humboldt-University of Berlin
Elke Schaeffner, MD, MSc
Seema Baid-Agrawal, MD
Kerstin Petzold, RN
Ralf Schindler, MD
University of Erlangen-Nürnberg
Carl F. Hilgers, MD
Silvia Hübner, MD
Susanne Avendano, RN
Dinah Becker-Grosspietsch, RN
University of Freiburg
Anna Köttgen, MD, MPH
Ulla Schultheiß, MD
Simone Meder, RN
Ema Mitsch, RN
Gerd Walz, MD
Hannover Medical School
Jan T. Kielstein, MD
Petra Otto, RN
Hermann Haller, MD
University of Heidelberg
Claudia Sommerer, MD
Claudia Föllinger, RN
Tanja Löschner, RN
Martin Zeier, MD
University of Jena
Martin Busch, MD
Katharina Paul, MSc
Lisett Ditrich
Gunter Wolf, MD, MHBA
Ludwig-Maximilians University of München
Thomas Sitter, MD
Robert Hilge, MD
Claudia Blank
University of Würzburg
Vera Krane, MD
Daniel Schmiedeke, MD
Sebastian Toncar, MD
Daniela Cavitt, RN
Christoph Wanner, MD

Study and data coordinating center

University of Erlangen-Nürnberg
Kai-Uwe Eckardt, MD (PI)
A list of nephrologists currently collaborating with the GCKD study is available at www.gckd.org

References

4. Gansevoort RT, Matsushita K, van der Velde M et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2010; 80: 2073–2081
17. Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol 1988; 17: 248–254


Received for publication: 26.5.11; Accepted in revised form: 4.7.11